Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 2020

View Archived Issues

New splicing factor implicated in muscular dystrophy

How cancer cells hibernate

Biallelic TKFC variants cause cataracts and human multisystem disease

CD206 activation by RP-182 improves adaptive and innate antitumor immunity by reprogramming TAMs

New CB1R agonist-positive allosteric modulators with improved drug-like physicochemical properties

New mouse model of gastric premalignancy integrating TP53 deletion with environmental exposures

FDA approves Pizensy for oral solution for chronic idiopathic constipation in adults

Givlaari receives European approval for Givlaari treatment of AHP in adults and adolescents

Phase II study of Diamyd in autoimmune diabetes opens for recruitment

uniQure and Gen-X collaborate to develop gene therapy synthetic promoters

Phase II data for nemolizumab in moderate-to-severe prurigo nodularis

PAR1 as a new therapeutic target for demyelinating disorders of the CNS

anti-SARS CoV antibody CR-3022 shows potent binding to 2019-nCoV spike protein

Bristol-Myers Squibb describes new protein-arginine deiminase type-4 inhibitors

New NLRP3 agonists discovered at Innate Tumor Immunity

Modern Biosciences patents anti-cancer compounds

First patient dosed in multiple ascending dose phase I study of LYT-100

Complement factor D inhibitors identified at Achillion

Medshine Discovery discloses new PI3K inhibitors

Nanoparticle vaccine elicits HBV therapeutic response

GBV-6249-192 demonstrates good preclinical results for treating primary open-angle glaucoma

Zydus receives approval to initiate phase I study of ZYBK-2 in India

Update for part A of ongoing phase I/IIa study of VBI-1901

NanoSurface announces NIH funding to support iPSC-based platform development

New phase II study investigates Telomelysin and radiotherapy for locally advanced esophageal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...